Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Operating Leases (2021 - 2025)

Senti Biosciences has reported Operating Leases over the past 5 years, most recently at $23.6 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 18.45% year-over-year to $23.6 million; the TTM value through Dec 2025 reached $23.6 million, down 18.45%, while the annual FY2025 figure was $23.6 million, 18.45% down from the prior year.
  • Operating Leases for Q4 2025 was $23.6 million at Senti Biosciences, down from $30.1 million in the prior quarter.
  • Over five years, Operating Leases peaked at $37.2 million in Q3 2023 and troughed at $21.0 million in Q4 2021.
  • A 5-year average of $31.9 million and a median of $32.3 million in 2022 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: soared 67.25% in 2022 and later fell 18.45% in 2025.
  • Year by year, Operating Leases stood at $21.0 million in 2021, then surged by 67.25% to $35.1 million in 2022, then dropped by 4.46% to $33.5 million in 2023, then decreased by 13.86% to $28.9 million in 2024, then fell by 18.45% to $23.6 million in 2025.
  • Business Quant data shows Operating Leases for SNTI at $23.6 million in Q4 2025, $30.1 million in Q3 2025, and $31.3 million in Q2 2025.